5-Amino-1MQ
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small synthetic molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is highly active in fat tissue. It is frequently grouped with fat-loss compounds, though unlike most compounds in that category it is not a peptide.
Interest in 5-Amino-1MQ comes from preclinical work suggesting that blocking NNMT may raise NAD+ levels inside fat cells and shift them toward burning energy rather than storing it. In diet-induced obesity models, treated animals showed reductions in body weight, white-fat mass, and fat-cell size.
The evidence base is young and comes almost entirely from in-vitro (cell) and rodent studies. No human clinical trials of NNMT inhibitors have been reported, so human effects, dosing, and safety remain unestablished.
How it works
NNMT consumes nicotinamide — a precursor the body uses to make NAD+ — along with S-adenosylmethionine, a universal methyl donor. By inhibiting NNMT, 5-Amino-1MQ is studied for its potential to spare both of those pools, which in preclinical models is associated with higher intracellular NAD+ and reduced fat storage (lipogenesis).
In cell studies, 5-Amino-1MQ emerged as a lead compound because it is selective for NNMT over related methyltransferases and is membrane-permeable, allowing it to reach the enzyme inside adipocytes. The precise relevance of these mechanisms to humans has not been established.
Reported benefits
- Reduced fat accumulation and smaller fat-cell size (rodent data)
- Increased NAD+ levels within fat cells (cell and animal data)
- Reduced body weight without changes in food intake (rodent data)
- Selective enzyme inhibition without affecting related NAD+ salvage pathways (preclinical)
These are reported findings from preclinical research, not guaranteed outcomes in humans.
Considerations & side effects
Because there are no published human trials, the safety profile and long-term effects of 5-Amino-1MQ in people are unknown. Rodent studies to date have not reported obvious adverse effects, but animal safety data does not reliably translate to humans.
As with other research chemicals sold outside the regulated supply chain, purity and identity can vary between sources. 5-Amino-1MQ is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is 5-Amino-1MQ?
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied mainly in cell and rodent models for its effects on fat-cell metabolism and NAD+ levels. It is a synthetic compound, not a peptide.
Is 5-Amino-1MQ FDA-approved?
No. It is not approved by the FDA or any major regulator for human therapeutic use, and no NNMT-targeting clinical trials have been reported. It is sold for research purposes only.
How does 5-Amino-1MQ differ from peptides like BPC-157?
It is a small synthetic molecule rather than an amino-acid chain. It works by inhibiting a metabolic enzyme, whereas most peptides act on receptors or signaling pathways.
Does it affect appetite?
In the rodent studies reported to date, food intake did not change even as body weight and fat mass decreased. Its studied effects are on metabolism rather than appetite.
References
Related compounds
5-Aminoimidazole-4-carboxamide ribonucleotide, an AMPK activator that mimics AMP to enhance metabolic activity and endurance. Preclinical exercise mimetic compound.
Lipotropic injection blend typically containing methionine, inositol, choline, and B12. Supports liver function and promotes fat metabolism.
Prohibitin-targeting peptidomimetic designed to selectively disrupt blood supply to white adipose tissue. Highly experimental anti-obesity compound. Clinical development discontinued due to renal side effects.